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Abstract: Paclitaxel is a treatment option for advanced or metastatic bladder cancer after the failure
of first-line cisplatin and gemcitabine, although resistance limits its clinical benefits. Mcl-1 is an
anti-apoptotic protein that promotes resistance to paclitaxel in different tumors. Obatoclax, a BH3
mimetic of the Bcl-2 family of proteins, antagonizes Mcl-1 and hence may reverse paclitaxel resistance
in Mcl-1-overexpressing tumors. In this study, paclitaxel-sensitive 5637 and -resistant HT1197 bladder
cancer cells were treated with paclitaxel, obatoclax, or combinations of both. Apoptosis, cell cycle, and
autophagy were measured by Western blot, flow cytometry, and fluorescence microscopy. Moreover,
Mcl-1 expression was analyzed by immunohistochemistry in bladder carcinoma tissues. Our results
confirmed that paclitaxel alone induced Mcl-1 downregulation and apoptosis in 5637, but not in
HT1197 cells; however, combinations of obatoclax and paclitaxel sensitized HT1197 cells to the
treatment. In obatoclax-treated 5637 and obatoclax + paclitaxel-treated HT1197 cells, the blockade of
the autophagic flux correlated with apoptosis and was associated with caspase-dependent cleavage of
beclin-1. Obatoclax alone delayed the cell cycle in 5637, but not in HT1197 cells, whereas combinations
of both retarded the cell cycle and reduced mitotic slippage. In conclusion, obatoclax sensitizes
HT1197 cells to paclitaxel-induced apoptosis through the blockade of the autophagic flux and effects
on the cell cycle. Furthermore, Mcl-1 is overexpressed in many invasive bladder carcinomas, and it is
related to tumor progression, so Mcl-1 expression may be of predictive value in bladder cancer.
Keywords: bladder cancer; obatoclax; paclitaxel; autophagy; apoptosis
1. Introduction
Urinary bladder cancer is a major cause of morbidity and mortality worldwide, with over 400,000
new cases diagnosed per year [1]. Most cases are urothelial carcinomas, which often present as
superficial papillary proliferations with a good overall survival rate. However, about thirty percent of
cases present as muscle-invasive carcinomas, which carry a higher risk of lethal metastatic disease [2].
Muscle-invasive bladder carcinoma may need radical surgery and adjuvant chemotherapy with
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gemcitabine or platinum, and relapsed or refractory cases may require second-line therapies, which
most often consist of chemotherapy with the microtubule toxins vinflunine, paclitaxel, or docetaxel [3].
These agents interfere with microtubule dynamics and activate the mitotic spindle assembly checkpoint
to arrest cells in mitosis; thereafter, cells may die promptly in mitosis or escape post-mitotically towards
other cell fates [4]. Paclitaxel and docetaxel are widely used in the treatment of various types of cancer,
but resistance and toxicity often limit their clinical efficacy. Since spindle assembly checkpoint proteins
are activated upon taxane treatment, they may be regarded as potential predictive markers of taxane
resistance [5]. Anti-apoptotic proteins may also be involved in taxane resistance. We have previously
shown that anti-apoptotic Mcl-1 is related to paclitaxel resistance in prostate and breast cancer and
that Mcl-1 over-expression is a frequent event in aggressive cancers [6–8].
Obatoclax (GX15-070), a small molecule of the class of BH3 mimetics, antagonizes the
anti-apoptotic Bcl-2 family of proteins by disrupting their interactions with Bax or Bak. This compound
potently inhibits the association of Mcl-1 with Bak and is able to kill Mcl-1 overexpressing cancer
cells, reverting Mcl-1-mediated resistance to Bcl-2/Bcl-xL/Bcl-w-selective antagonist ABT-737 [9,10].
Obatoclax has proven anti-tumor activity for several hematological malignancies when used as a
single-agent therapy [11,12]. Based on its antagonistic role of the anti-apoptotic Bcl-2 family of proteins,
obatoclax was first described to induce apoptotic cell death [9,13]. Other non-apoptotic forms of cell
death, particularly autophagy, have also been demonstrated to play a role in obatoclax-mediated
cytotoxicity, and several studies showed that the blockade of autophagy resulted in cell death since
autophagy inhibitors potentiated the cytotoxicity of obatoclax [14–18]. Furthermore, it has been
reported that obatoclax induces the alkalization and destabilization of lysosomes after the blockade
of autophagic flux as a mechanism of cytotoxicity [19–21], and other cell death mechanism such as
necroptosis have also been described [22,23].
There are many links between the pathways of apoptosis and autophagy. For example, anti-
apoptotic protein Bcl-2 interacts with autophagy-related protein beclin-1 to inhibit beclin-1-dependent
autophagy [24]. Bim, another Bcl-2 family member, can inhibit autophagy by recruiting beclin-1
to microtubules where Bim associates with dynein LC8 in the absence of apoptotic stimuli [25].
Furthermore, autophagy-related (Atg) proteins can be cleaved by cell death proteases calpain-1 and
caspases-3, -6, and -8, providing the potential regulation of autophagy, as well as novel pro-apoptotic
functions of cleaved fragments [26]. The caspase-mediated cleavage of beclin-1 was shown to yield
fragments that lack the autophagy-inducing capacity of intact beclin-1, as well as a C-terminal fragment
that localized predominantly in the mitochondria and sensitized cells to apoptosis [27].
In this study, we analyze the expression of Mcl-1 in a series of superficial and muscle-invasive
bladder cancer patients and in paclitaxel-sensitive 5637 and paclitaxel-resistant HT1197 cell lines in
response to paclitaxel and obatoclax treatment. We demonstrate that the Mcl-1 antagonist obatoclax,
given in combination with paclitaxel, is able to sensitize resistant cells to apoptotic cell death. We
investigate the effects of obatoclax and combinations of obatoclax and paclitaxel on the cell cycle
and the crosstalk between apoptosis and autophagy. We show that in paclitaxel-resistant cancer cells,
the combination of obatoclax with paclitaxel retards the cell cycle, inhibiting mitotic slippage and
promoting the blockade of the autophagic flux to facilitate paclitaxel-induced apoptosis.
2. Results
2.1. Decrease of Mcl-1 and Apoptosis Concur in Paclitaxel-Treated 5637, but Not in HT1197 Bladder
Cancer Cells
We used 5637 and HT1197 bladder cancer cells to investigate the mechanisms of bladder cancer
response to taxanes. Cells were treated with 0.1 µM paclitaxel for 24 and 48 h, and apoptosis was
monitored by Western blot (Figure 1a). Apoptotic cell death was induced in 5637 cells, as shown
by cleavage of PARP, caspase-9, and caspase-3, which were activated upon treatment. Paclitaxel in
5637 cells also decreased Mcl-1 levels and induced the phosphorylation of Bcl-xL, thus inhibiting the
anti-apoptotic properties of this protein. Levels of pro-apoptotic Bax and Bak did not change after
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paclitaxel treatment. In contrast, paclitaxel did not induce apoptosis in HT1197 cells, as shown by
the absence of cleavage of PARP, caspase-9, and caspase-3. Importantly, Mcl-1 levels did not drop in
HT1197 cells, and Bcl-xL remained unphosphorylated, which suggests that these mechanisms may
contribute to paclitaxel resistance.
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Figure 1. Downregulation of Mcl-1 is necessary for paclitaxel-induced apoptosis of bladder cancer
cells. (a,b) 5637 and HT1197 cells were treated with dimethyl sulfoxide (DMSO) or 0.1 µM paclitaxel
for 24 and 48 h. Western blot analyses of PARP, cleaved caspase-3, cleaved caspase-9, Mcl-1, Bcl-xL,
Bax, Bak, cyclin B1, and p-histone H3Ser10 are shown. β-actin was used as a loading control. (c) Cells
were subjected to FISH with a centromeric probe specific for chromosome 17 (Spectrum green). DNA
was stained with DAPI (blue). At least 100 cells were counted for each condition, and the percentage
of cells with normal ploidy or higher ploidy is presented in the histogram. Representative images
are shown. Photomicrographs were taken using a 40× objective. (d) The expression of Mcl-1 was
evaluated in samples of 72 patients with muscle-invasive or non-muscle-invasive bladder carcinoma
by immunohistochemistry and quantified in the histogram. The relationship between the levels
of expression of Mcl-1 and tumor infiltration in patients with bladder carcinoma was statistically
significant. p-values were obtained using Fisher’s exact test. NMIBC: non-muscle-invasive bladder
cancer; MIBC: muscle-invasive bladder cancer. Bars represent 100 µm. (e) Kaplan–Meier analysis
of recurrence-free survival in patients with low (blue) and high (red) Mcl-1 expression. Tick marks
represent censored patients. p-value < 0.0001 was obtained using the log-rank test of Mantel and Cox.
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To check whether the bladder cancer cells were arrested in mitosis upon paclitaxel treatment
or could escape by slippage, the levels of cyclin B1 and p-histone H3Ser10 were analyzed (Figure 1b).
In paclitaxel-sensitive 5637 cells, the levels of cyclin B1 and p-histone H3Ser10 increased after 24 h
and decreased after 48 h of paclitaxel treatment. In paclitaxel-resistant HT1197 cells, these mitotic
proteins behaved similarly after paclitaxel treatment, with an increase in protein levels at 24 h and a
decrease at 48 h. Thus, both cell lines are first arrested in mitosis and then exit mitosis by slippage.
Analysis by FISH (Figure 1c) demonstrated that more than 80% of 5637 cells exhibited a duplicated
DNA ploidy before late apoptosis as a result of mitotic slippage. Similarly, more than 90% of HT1197
cells had duplicated DNA ploidy upon paclitaxel treatment. These results indicate that 5637 and
HT1197 cells share common mechanisms to escape paclitaxel-induced mitotic arrest, but only 5637
cells suffer apoptosis after mitotic slippage.
Mcl-1 may have major roles in the distinct responses to paclitaxel in these bladder cancer cells
and, therefore, is a good candidate to predict paclitaxel response in the clinical setting. Accordingly,
we used immunohistochemistry to analyze the expression of Mcl-1 in biopsies from 72 bladder
carcinomas (53 non-muscle-invasive, 19 muscle-invasive) (Figure 1d and Supplementary Table S1).
Most non-muscle-invasive bladder carcinomas (96.2%) showed very low levels of Mcl-1. On the other
hand, 12 out of 19 (63.2%) muscle-invasive bladder carcinomas showed increased levels of Mcl-1.
Regarding the prognostic role of Mcl-1 expression, we performed a Kaplan–Meier study where we
observed that high Mcl-1 levels were related to a lower disease free survival and a higher risk of
patient recurrence, indicating that Mcl-1 could be a good prognostic marker of tumor aggressiveness
(Figure 1e).
2.2. The Combination of Paclitaxel and Mcl-1 Antagonist Obatoclax Induces Apoptosis in Resistant
HT1197 Cells
As mentioned, Mcl-1 may mediate paclitaxel resistance in bladder cancer cells and is highly
expressed in many muscle-invasive bladder carcinomas. Obatoclax antagonizes Mcl-1 and induces cell
death in hematological tumors [11,12], so we decided to study obatoclax effects in paclitaxel-sensitive
and paclitaxel-resistant bladder cancer cells. We treated 5637 and HT1197 cells with 1 µM obatoclax
either alone or in combination with 0.1 µM paclitaxel (Figure 2). In the latter, cells were treated with one
drug for 8 h, and the other drug was added for 40 h or cells were treated with both drugs at the same
time for 48 h. Paclitaxel-sensitive 5637 cells were responsive to obatoclax alone and in combination
with paclitaxel, as shown by PARP cleavage and caspase-3 activation in all conditions. Moreover, Mcl-1
levels decreased after all of the treatments, while Bak levels showed no change. In the case of HT1197
cells, we observed no PARP cleavage, caspase-3 activation, or Mcl-1 decrease using either obatoclax or
paclitaxel as single treatments. However, all three combinations of obatoclax and paclitaxel were able
to induce apoptosis and also decrease Mcl-1 expression in HT1197 cells. Therefore, the combination of
paclitaxel with obatoclax overcame the paclitaxel resistance of HT1197 cells.
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h. The combinations were: obatoclax followed by paclitaxel after 8 h, paclitaxel followed by obatoclax
after 8 h, and both at the same time. In the 5637 and HT1197 cell lines, Western blot analyses of PARP,
cleaved caspase 3, Mcl-1, and Bak are shown. β-actin is shown as a loading control. Histograms
show the densitometric analysis of indicated proteins. Data are presented as the mean ± SD, and each
treatment was compared with DMSO as the control. * p-value < 0.05 and ns indicates non-significant
differences from Student’s t-test (n ≥ 3). OBT: obatoclax; PTX: paclitaxel.
2.3. LC3-II and p62 Accumulate in 5637 Cells reate it t lax and HT 197 Cells Treated with
Combinations of Obatoclax and Paclitaxel
Cyto xicity mediated by obat clax has been associ ted with autoph gy rocesses. We proceeded
to study the autophagic flux in 5637 and HT1197 cells treated with obatoclax or combinations of
obatoclax and paclitaxel and its relationship with cell deat or survival. First, cells were treated with
1 µM obatoclax for 48 h in the presence or absence of 400 nM bafilomycin A1 (BafA1), an autophagic
flux inhibitor, added for the last 4 h of treatment. Autophagic flux was monitored by Western blot
of LC3-Band p62 (Figure 3a, Supplementary Figure S1a). In 5637 cells, obatoclax alone induced the
accumulation of LC3-II and p62 more so than after the addition of BafA1. This accumulation reflects
that obatoclax alone is able to cause an efficient blockade of the autophagic flux in 5637 cells. In
contrast, obatoclax alone did not increase the protein levels of LC3-II and p62 in HT1197 cells as much
as in 5637 or after the addition of BafA1, reflecting a less efficient blockade of the autophagic flux by
obatoclax in HT1197 cells. Then, 5637 and HT1197 cells were treated with obatoclax, paclitaxel, and
the combinations of obatoclax and paclitaxel, and the autophagic flux was studied by Western blot
of LC3-Band p62 (Figure 3b, Supplementary Figure S1b). Paclitaxel alone did not increase the levels
of LC3-II and p62 in either 5637 or HT1197 cells. All three combinations of obatoclax and paclitaxel
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induced the accumulation of LC3-II and p62 in 5637 cells and, interestingly, in HT1197 cells, in which
the blockade of the autophagic flux may act as a mechanism of sensitization to paclitaxel.
Cancers 2018, 10, x 6 of 17 
 
in HT1197 cells, in which the blockade of the autophagic flux may act as a mechanism of sensitization 
to paclitaxel. 
 
Figure 3. LC3-II and p62 accumulate in obatoclax-treated 5637 cells and HT1197 cells treated with 
obatoclax plus paclitaxel. The cleavage of beclin-1 by caspase 3 induces apoptosis as a mechanism of 
sensitization. (a) Cells were treated with DMSO or 1 µM obatoclax for 48 h, in the absence or presence 
of the autophagy inhibitor bafilomycin A1 400 nM for 4 h. (b) Cells were treated with 1 μM obatoclax, 
0.1 µM paclitaxel, and combinations of both for 48 h. Western blot analyses of LC3-B and p62 are 
shown. β-actin is shown as a loading control. OBT: obatoclax; PTX: paclitaxel. (c) The 5637 cell line 
was treated with DMSO or 1 µM obatoclax for 48 h in the presence or absence of pre-incubation with 
pan-caspase inhibitor Z-VAD-fmk 20 µM for 1 h. (d) 5637 and HT1197 cells were treated with DMSO, 
1 μM obatoclax, or 1 μM obatoclax plus 0.1 μM paclitaxel for 48 h. Western blot analyses of beclin-1 
and cleaved caspase-3 are shown. Symbol ◄ indicates an unspecific band of 50-kDa beclin-1. β-actin 
is shown as a loading control. 
2.4. Caspase-Dependent Cleavage of Beclin-1 Associates with Autophagy Blockade and Apoptosis in HT1197 
Cells Treated with a Combination of Obatoclax and Paclitaxel 
Beclin-1 shares a BH3-like domain with the anti-apoptotic members of the Bcl-2 family. Its 
interaction with Bcl-2 or Bcl-xL has inhibitory actions on autophagy, and its cleavage by caspase-3 
regulates crosstalk between apoptosis and autophagy [24,27]. We analyzed the role of beclin-1 in the 
blockade of the autophagic flux and induction of apoptosis in cells treated with obatoclax or a 
combination of obatoclax and paclitaxel. First, 5637 cells were treated with 1 µM obatoclax in the 
presence or absence of caspase inhibitor Z-VAD-fmk, and beclin-1 was analyzed by Western blot 
(Figure 3c). Obatoclax treatment induced the cleavage of beclin-1, as shown by the appearance of 35- 
Figure 3. LC3-II and p62 accumulate in obatoclax-treated 5637 cells and HT1197 cells treated with
obatoclax plus paclitaxel. The cleavage of beclin-1 by caspase 3 induces apoptosis as a mechanism of
sensitization. (a) Cells were treated with DMSO or 1 µM obatoclax for 48 h, in the absence or presence
of the autophagy inhibitor bafilomycin A1 400 nM for 4 h. (b) Cells were treated with 1 µM obatoclax,
0.1 µM paclitaxel, and combinations of both for 48 h. Western blot analyses of LC3-B and p62 are
shown. β-actin is shown as a loading control. OBT: obatoclax; PTX: paclitaxel. (c) The 5637 cell line
was treated with DMSO or 1 µM obatoclax for 48 h in the presence or absence of pre-incubation with
pan-caspase inhibitor Z-VAD-fmk 20 µM for 1 h. (d) 5637 and HT1197 cells were treated with DMSO,
1 µM obatoclax, or 1 µM obatoclax plus 0.1 µM paclitaxel for 48 h. Western blot analyses of beclin-1
and cleaved caspase-3 are shown. Symbol J indicates an unspecific band of 50-kDa beclin-1. β-actin is
shown as a loading control.
2.4. Caspase-Dependent Cleavage of Beclin-1 Associates with Autophagy Blockade and Apoptosis in HT1197
Cells Treated with a Combination of Obatoclax and Paclitaxel
Beclin-1 shares a BH3-like domain with the anti-apoptotic members of the Bcl-2 family. Its
interactio wit Bcl-2 or Bcl-xL has inhibitory actio s on aut phagy, and its cleavage by caspase-3
regulates crosstalk between apoptosis and autophagy [24,27]. We an lyzed the role of beclin-1 in
the blockade of the autophagic flux and induction of apoptosis in cells treated with obatoclax or a
combinati n of obat clax and paclitaxel. First, 5637 cells were treated with 1 µM obatoclax in the
presence r absence of caspase inhibitor Z-VAD-fmk, and beclin-1 was analyzed by Western blot
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(Figure 3c). Obatoclax treatment induced the cleavage of beclin-1, as shown by the appearance of 35-
and 37-kDa fragments. Cleavage of beclin-1 was caspase-dependent, as fragments were not seen in the
presence of caspase inhibitor Z-VAD-fmk. Then, we compared the cleavage of beclin-1 in 5637 and
HT1197 cells treated with obatoclax alone or in combination with paclitaxel (Figure 3d, Supplementary
Figure S1c). Again, cleavage of beclin-1 was observed in 5637 cells treated with obatoclax or with the
combination of both drugs. In HT1197 cells, treatment with obatoclax alone did not induce cleavage of
beclin-1. However, the combination of obatoclax and paclitaxel resulted in the appearance of 35- and
37-kDa fragments in the Western blot, reflecting that beclin-1 was cleaved and complete autophagy
achieved. This mechanism may help to induce apoptosis when paclitaxel-resistant cells are treated
with a combination of obatoclax and paclitaxel.
2.5. Blockade of the Autophagic Flux Correlates with Apoptotic Cell Death in HT1197 Cells Treated with a
Combination of Obatoclax and Paclitaxel
To evaluate autophagic flux inhibition, cells were treated with 1 µM obatoclax alone or in
combination with 0.1 µM paclitaxel for 48 h, with 800 nM rapamycin as the control for autophagic
flux induction and 50 µM chloroquine as the control for autophagic flux inhibition (DMSO was used
as the negative control). After treatment, cells were loaded with Cyto-IDTM (Enzo Life Sciences,
Farmingdale, NY, USA) Green dye and then analyzed by flow cytometry (Figure 4a). Using this
method, fluorescence intensity correlates with the accumulation of autophagy vesicles as a result of
inhibition of the autophagic flux. Mean fluorescence intensity for each condition was expressed as a
fold change as compared to DMSO. In 5637 cells, obatoclax alone and the combination of obatoclax
and paclitaxel caused a higher fluorescence intensity than that induced by chloroquine, reflecting
a low autophagic flux. In HT1197 cells, obatoclax alone induced a similar fluorescence intensity
to that induced by rapamycin, suggesting that high autophagic flux was turned on in these cells.
The combination of obatoclax and paclitaxel was able to inhibit autophagic flux in HT1197 cells, as
shown by a similar fluorescence intensity to that induced by chloroquine. Next, we used fluorescence
microscopy to analyze the formation of different autophagy compartments since Cyto-IDTM Green dye
labels the autophagosomes with minimal staining of lysosomes or endosomes (Figure 4b). Cyto-IDTM
Green dye revealed the formation of autophagosomes that do not fuse with lysosomes by means of
perinuclear or cytoplasmic puncta in 5637 cells treated with obatoclax alone or in combination with
paclitaxel. Counterstaining with Hoechst 33342 dye revealed nuclear fragmentation and the formation
of apoptotic bodies in 5637 cells under both treatments. In HT1197 cells, obatoclax alone did not form
Cyto-IDTM Green dye-labeled puncta, but rather dark autophagolysosomes, indicating that autophagy
was complete. Nuclear staining with Hoechst 33342 showed no apoptotic damage. However, the
combination of obatoclax and paclitaxel was able to induce the accumulation of autophagosomes,
labeled by the Cyto-IDTM Green dye, and the apoptotic fragmentation of nuclei in HT1197 cells,
reflecting that sensitization with obatoclax blocks the autophagic flux and facilitates paclitaxel-induced
apoptosis in these cells.
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Figure 4. Autophagic flux blockade correlates with apoptotic cell death in obatoclax plus
paclitaxel-treated HT1197 cells. Cells were treated with 1 µM obatoclax or 1 µM obatoclax and
0.1 µM paclitaxel for 48 h. DMSO, 800 nM rapamycin, and 50 µM chloroquine were used as controls.
(a) Obatoclax-blocked autophagic flux at 48 h was measured by flow cytometry-based profiling of
Cyto-IDTM Autophagy Detection in 5637 and HT1197 cell lines. Histograms show the mean intensity
of each tr atment. Data were pr sented as the mean ± SD. * p-value < 0.05 from Student’s t-test (n ≥ 3).
(b) Colocalization of the Cyto-IDTM fluorescent dye and Hoechst 3342 in 5637 and HT1197 cells.
Photomicrographs were taken using a 100× objective under an inverted fluoresc n microsc pe. OBT:
obatoclax; PTX: paclitaxel.
2.6. Obatoclax Retards the Cell Cycle of Paclitaxel-Treated T1197 Cells and Favors Inhibition of
Mitotic Slippage
We studied the effects of obatoclax and the combinations of obatoclax and paclitaxel on the cell
cycle of 5637 and HT1197 cells. content was analyzed by flow cytometry 24 h and 48 h after
the different treatment combinations (Figure 5a). Obatoclax alone increased t e S-phase cell count
at 48 h as compared with 24 h in 5637 cells, but not in HT1197 cells, which showed similar S-phase
cell counts at 24 h and 48 h. Paclitaxel alo e induced G2/M arrest at 24 h in both 5637 and HT1197
cells that persisted at 48 h, although this peak may b enriched in cells wit higher ploidy. All three
combinations of paclitaxel and obatoclax ar ested 5637 l M at 48 h, bu the highest S-phase
cell counts at 24 h where observed when obatoclax was dded first. In contrast, the same combinations
retarded the cell cycle in HT1197 cells, as shown by a higher G1-phase percentage compared with
5637 cells. As mentioned, paclitaxel treatment induces mitotic slippage in both 5637 and HT1197 cell
lines, but with different end effects, i.e., cell death or survival, respectively. We performed ploidy
analysis by FISH to study the effects of the combination of paclitaxel and obatoclax on mitotic slippage
(Figure 5b). Obatoclax alone did not alter ploidy in 5637 cells, as opposed to paclitaxel, which increased
ploidy in these cells. The combination of paclitaxel and obatoclax in 5637 cells had different effects
depending on the treatment sequence: obatoclax followed by paclitaxel had a similar effect on ploidy
as obatoclax alone, whereas paclitaxel followed by obatoclax or both drugs added together increased
ploidy in 5637 cells. This means that obatoclax alone or when added first may induce cell death
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in 5637 cells before mitosis, but when paclitaxel is added first or together with obatoclax, mitotic
slippage is the principal means of cell death. In HT1197 cells, obatoclax alone did not change ploidy,
as compared with DMSO. Paclitaxel alone increased ploidy of HT1197 cells, a sign of mitotic slippage
as a mechanism of resistance in these cells. None of the three combinations of paclitaxel and obatoclax
changed ploidy in HT1197 cells, reflecting that paclitaxel-induced G2/M arrest was more efficient and
mitotic slippage restrained.
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2.7. Combinations of Obatoclax and Paclitaxel Promote Apoptosis in Paclitaxel-Resistant HT1376 and
MDA-MB-231 Cells
To confirm these results, we analyzed two further cancer cell lines, HT1376 (bladder cancer)
and MDA-MB-231 (breast cancer) cells, that are resistant to paclitaxel, but, in contrast with HT1197,
more sensitive to obatoclax as a single treatment. These cells were treated with 1 µM obatoclax,
0.1 µM paclitaxel, or combinations, as described. In both cell types, all combinations of obatoclax and
paclitaxel were able to induce higher levels of apoptosis than obatoclax or paclitaxel alone, as shown
by cleavage of PARP and caspase-3, besides decreasing Mcl-1 levels (Figure 6a, Supplementary Figures
S2a and S3a). We checked the autophagic flux by Western blot of LC3-B and p62, and all combinations
of obatoclax and paclitaxel were able to maintain the blockade of the autophagic flux, as seen with
obatoclax alone in both cell lines (Figure 6a, Supplementary Figures S2a and S3a).
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Figure 6. The combination of paclitaxel a t clax in HT1376 and MDA-MB-231 cells overcomes
paclitaxel resistance. HT1376 and - B-231 cells were treated with 1 µM batoclax, 0.1 µM
paclitaxel, and combinations of both for 48 h. (a) Western blot analyses of PARP, cleaved caspase-3,
Mcl-1, p62, and LC3-B are shown. β-actin was used as a loading control. (b) Cell cycle analysis
of propidium iodide-stained cells by flow cytometry. The quantification of each phase is shown in
the histograms. (c) Cells were subjected to FISH with a centromeric probe specific for chromosome
17 (Spectrum green). DNA was stained with DAPI (blue). At least 100 cells were counted for each
condition, and the percentage of cells with normal ploidy or higher ploidy is presented in the histogram.
Cell cycle analysis of HT1376 cells treated with obatoclax alone showed no dramatic effects with
respect to DMSO at 24 h and 48 h as previously observed for HT1197; however, in MDA-MB-231 breast
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cancer cells, obatoclax alone clearly increased S-phase. Paclitaxel alone induced G2/M arrest at 24 h,
which persisted at 48 h in both cell types. Combinations of obatoclax and paclitaxel increased S-phase
with respect to paclitaxel alone, particularly when obatoclax was added first (Figure 6b, Supplementary
Figures S2b and S3b). FISH analysis showed that obatoclax alone did not change the ploidy of HT1376
or MDA-MB-231 cells. In contrast, paclitaxel increased the ploidy as a sign of mitotic slippage in both
cell types. Combinations of obatoclax and paclitaxel were able to reduce the number of cells with
higher ploidy with respect to paclitaxel alone, reflecting that mitotic slippage inhibition may also
account for apoptotic cell death.
3. Discussion
Paclitaxel is used in the second-line therapy of advanced urothelial cancer, but resistance and
toxicity limit its clinical benefits. Elucidation of the mechanisms of paclitaxel resistance may help
to identify biomarkers for the development of alternative or sensitizing therapies. We previously
showed that Mcl-1 is a determinant of the response to paclitaxel treatment, is overexpressed in many
paclitaxel-resistant tumors, and that downregulation of Mcl-1 restores the sensitivity to paclitaxel [6–8].
Herein, we show that Mcl-1 is downregulated in sensitive 5637 cells, but not in resistant HT1197 cells
in response to paclitaxel and that Mcl-1 is overexpressed in many muscle-invasive bladder carcinomas.
The relevance of Mcl-1 as a biomarker of aggressiveness is well described in several malignancies, and
its overexpression has also been related to the resistance of several BH3 mimetics [28–30]. We found
that combinations of obatoclax and paclitaxel were able to induce apoptotic cell death in resistant
HT1197 cells, as well as in other models of paclitaxel resistance such as HT1376 and MDA-MB-231
cells. Other authors have studied the role of obatoclax in paclitaxel sensitization in several cells
lines. Stamelos et al. used a combination of both drugs and did not observe any sensitization to
paclitaxel in ovarian cancer cells, although obatoclax sensitized cells to carboplatin treatment [20].
In hepatoblastoma cells, the combination of obatoclax with paclitaxel was reported to have additive
effects, with a loss of cell viability [31].
Although several mechanisms have been implicated in the induction of obatoclax cell
death—apoptosis, necroptosis, and autophagy—they are still not completely understood [14–16,19,32].
Several studies point to the blockade of autophagy as a mechanism of obatoclax toxicity due to
lysosome impairment. In this sense, Champa et al. reported that short obatoclax treatment induces
necrotic cell death in thyroid cancer cells by the destabilization of lysosomes after the blockade of the
autophagic flux [19], and Stamelos et al. also found that obatoclax accumulates in lysosomes, inducing
their alkalization and impairment in ovarian cancer cells, but without clear apoptosis induction [20],
thus arguing that there must be other mechanisms of cell death other than apoptosis in ovarian cancer
cells after obatoclax treatment. Moreover, in esophageal cancer cells, obatoclax has been reported
to block autophagy by the impairment of the lysosome, inducing a cytotoxic effect with diminished
cell viability [21]. Deregulation of autophagy has been implicated in many diseases, although the
relationship between autophagy and apoptosis is still a matter of controversy. However, several studies
indicate that these two processes are related and are important to the chemotherapy response [27,33].
Our results clearly show that obatoclax induces autophagy in bladder cancer cells and that this may be
accompanied by apoptotic cell death after the blockade of the autophagic flux, which could contribute
to the paclitaxel sensitization in paclitaxel-resistant cells. However, these processes are opposite and
do not co-occur, since we just observe apoptosis when the autophagy is blocked. It is important to
note that when autophagy is completed, as observed in the HT1197 cells as a mechanism of resistance,
obatoclax does not induce cell death. This observation is in agreement with several studies that have
shown that autophagy plays a protective role enhancing cellular survival in response to stress [34] and
drug-resistance after chemotherapy treatment [35,36]. This “dual” role may be due to the difference in
the autophagic flux, since it is not only important whether autophagy is occurring, but also whether
the induced autophagy is completed. Thus, in agreement with our results observed for the obatoclax
plus paclitaxel treatment of paclitaxel-resistant HT1197, HT1376, and MBA-MB-231 cancer cells, the
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autophagy blockade increases the therapeutic efficacy of chemotherapy in several malignancies [37,38]
and induces apoptosis [39].
Beclin-1 is a molecule with a role in the initiation of autophagy after nutrient starvation and is also
a caspase substrate, connecting autophagy with Bcl-2 family members via its BH3 domain [40]. Indeed,
Wirawan et al. reported a novel pro-apoptotic function of beclin-1, demonstrating that the cleavage of
becline-1 by caspase-3 results in the generation of a fragment that induces the inhibition of autophagy
and the amplification of apoptosis via the release of cytochrome C from the mitochondria [27].
Other authors reported that the specific blockage of beclin-1 cleavage induces autophagy in cells
treated with caspase inhibitors, indicating that beclin-1 cleavage by caspases is sufficient to suppress
autophagy [41]. In this work, we observed that obatoclax treatment induced apoptotic cell death
in the 5637 bladder cell line, and this was accompanied by beclin-1 cleavage and blockade of the
autophagic flux. Furthermore, we demonstrated that the HT1197 bladder cancer cell line is resistant to
obatoclax treatment when autophagy is complete; however, when we used obatoclax in combination
with paclitaxel, apoptotic cell death was induced after the autophagy blockade and beclin-1 cleavage.
Furthermore, the Mcl-1/Beclin-1 interaction has a role in the induction of autophagy and the survival of
cells under stress conditions [40]. This phenomenon could induce the disruption of the Mcl-1/beclin-1
interaction that promotes Mcl-1 degradation and beclin-1 cleavage in a caspase-3-dependent manner
and could be responsible for the apoptosis observed after the combination treatment.
Finally, we demonstrated that obatoclax treatment increased the S-phase in 5637 bladder and
MDA-MB 231 breast cancer cells (but did not alter the cell cycle in HT1197 bladder cancer cells) and
related the increment of the S-phase to apoptotic cell death. Our results differ from previous studies
with colorectal [42] and esophageal [43] cancer cells, where a growth inhibitory dose of obatoclax
caused arrest in G1 with some delay in the cell cycle progression not related to apoptotic cell death.
Furthermore, the combinations of obatoclax and paclitaxel were not only able to retard the cell cycle
progression in paclitaxel-resistant HT1197cells, but also to prevent the mitotic slippage that occurs
when these cells are treated with paclitaxel alone. In these conditions, Mcl-1 was downregulated
in HT1197 cells treated with combinations of obatoclax and paclitaxel, and we postulate that the
cell cycle arrest facilitates the degradation of Mcl-1. Previous reports highlighted the importance
of Mcl-1 ubiquitination and destruction by the proteasome for the promotion of apoptosis during
the prolonged mitotic arrest induced by microtubule toxins [8,44,45]. We suggest that the inhibition
of mitotic slippage and the delay of cell cycle progression observed after combination treatment in
HT1197 cells could increase the degradation of Mcl-1 by some ubiquitin ligases and thus influence the
stability of Mcl-1 in mitosis, helping cell sensitization to paclitaxel. The same results were seen in two
more paclitaxel-resistant bladder and breast cancer cell lines, so we can conclude that obatoclax helps
to overcome paclitaxel sensitization by arresting cells in the S/G2-phase to escape mitotic slippage as a
mechanism of resistance.
4. Materials and Methods
4.1. Cell Culture and Drugs
Human 5637 and HT1197 bladder cancer cells and MDA-MB-231 breast cancer cells were ordered
from the Interlab Cell Line Collection (Genoa, Italy), and HT1376 bladder cancer cells were from Sigma
(St. Louis, MO, USA). All experiments were performed using cells that had not exceeded the first ten
passages after receipt of the initial vial and were routinely tested for Mycoplasma contamination. Cells
were cultured in RPMI-1640 (Lonza, Basel, Switzerland) supplemented with 10% fetal bovine serum
(Biochrom, Cambridge, UK), 50 U/mL penicillin and 50 mM streptomycin (Sigma), 10 mM HEPES
(Lonza) and 1 mM glutamine (Gibco, Thermo Fisher Scientific, Waltham, Massachusetts, USA) at 37 ◦C
in a humidified incubator under 5% CO2. The stock solutions of paclitaxel (Calbiochem, San Diego,
CA, USA) and obatoclax (Selleck, Houston, TX, USA) were prepared at 10 mM in dimethyl sulfoxide
(DMSO, Sigma) and stored at −20 ◦C. In all experiments, cells were treated with either drug or vehicle
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during the log phase of growth. Cells were treated with 1 µM obatoclax or 0.1 µM paclitaxel either as
single treatment for 48 h or in combination: one drug for 8 h; and then, the other drug was added for
40 h or both drugs were added simultaneously for 48 h. The stock solutions of bafilomycin A1 and
z-VAD-fmk (Selleck) were prepared at 10 mM in DMSO, and rapamycin and chloroquine (Enzo Life
Sciences) were prepared at 60 mM and 500 µM, respectively, and stored at −20 ◦C.
4.2. Antibodies
Mouse monoclonal anti-PARP (1:500), anti-beclin-1 (1:500), rabbit polyclonal anti-Bax (1:2000),
and anti-Bak (1:3000) were from BD Biosciences (San Jose, CA, USA); mouse monoclonal anti-Bcl-xL
(1:1000), rabbit polyclonal anti-Mcl-1 (1:1000), anti-cyclin B1 (1:500), and anti-p-histone H3 (Ser10)
(1:1000) were from Santa Cruz (Santa Cruz, CA, USA); mouse monoclonal anti-β-actin (1:10,000), rabbit
polyclonal anti-LC3B (1:2000), and anti-p62 (1:2000) were from Sigma; rabbit polyclonal anti-cleaved
caspase-9 (Asp315) (1:500) and anti-cleaved caspase-3 (Asp175) (1:500) were from Cell Signaling
(Danvers, MA, USA).
4.3. Western Blot
Cells were lysed in Nonidet P-40 (NP40) lysis buffer (10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10%
glycerol, and 1% NP40). Equal amounts of total protein, as determined by the BCA protein assay kit
(Pierce, Rockford, IL, USA), were separated by SDS-PAGE on 8% polyacrylamide gels and transferred
to Hybond ECL nitrocellulose membranes (GE Healthcare, Europe GmbH, Freiburg, Germany). Blots
were stained with Ponceau S to ensure protein amounts were equal. For immunodetection, blots
were soaked in 1% blocking reagent (Roche, Basel, Switzerland) in 0.05% Tween 20-PBS for 1 h and
incubated with primary antibody in blocking buffer overnight at 4 ◦C. Blots were then washed in
0.05% Tween 20-PBS and incubated with either goat anti-mouse IgG (1:20,000; GE Healthcare) or
goat anti-rabbit IgG (1:20,000; GE Healthcare) peroxidase-labeled antibodies in blocking buffer for
1 h. An enhanced chemiluminescent ECL system (GE Healthcare) was applied according to the
manufacturer’s protocol. The experiments were performed in triplicate. Scanning densitometry of
blots was analyzed using ImageJ software (Rasband, W.S., US National Institutes of Health, Bethesda,
MD, USA, http://imagej.nih.gov/ij/).
4.4. Flow Cytometric Analysis of Cell Cycle
Cells were trypsinized and fixed in 70% ethanol. Propidium iodide staining of nuclei was
performed with the CycleTest Plus DNA reagent kit (BD Biosciences). DNA content was measured
using CellQuest Pro software in a FACScan flow cytometer (BD Biosciences).
4.5. Fluorescence In Situ Hybridization
Cells were imprinted onto silanized slides and fixed in ice-cold methanol/glacial acetic acid (3:1).
Slides were immersed in a 2× SSC (Saline Sodium Citrate)/0.3% NP40 solution at 37 ◦C during 30 min
and then dehydrated. Cellular DNA and the Spectrum green-labeled chromosome 17 centromeric
probe (Vysis) were co-denatured at 72 ◦C for 5 min and hybridized at 37 ◦C overnight. Slides were
washed in 2× SSC/0.3% NP40 at 72 ◦C for 5 min, counterstained with DAPI, and visualized using a
fluorescence microscope (Leica, Wetzlar, Germany). At least 100 cells were counted to calculate the
percentage of cells with normal ploidy and higher ploidy in each condition.
4.6. Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues from the transurethral resections of 72 patients with
bladder carcinoma were selected to make tissue microarrays with 1 mm cores in duplicate. The
study was approved by the local ethical committee. Five-micrometer tissue sections were dewaxed,
rehydrated, and immersed in 3% H2O2 aqueous solution for 30 min to exhaust endogenous peroxidase.
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Heat-induced epitope retrieval was performed with 1 mM EDTA (pH 9.0) in a microwave oven.
Sections were incubated overnight at 4 ◦C with anti-Mcl-1 antibody (1:1500). Peroxidase-labeled
secondary antibody and 3,3′-diaminobenzidine were applied according to the manufacturer’s protocol
(Dako, Glostrup, Denmark). Slides were then counterstained with hematoxylin and mounted.
Immunostains were scored as low (nil or < 10% positive cells) or high Mcl-1 expression (≥ 10%
positive cells).
4.7. Fluorescent Autophagy Detection Assay
The Cyto-IDTM Autophagy Detection kit (Enzo) was used in order to detect the autophagic flux.
Cells were treated with 1 µM obatoclax or 0.1 µM paclitaxel and 1 µM obatoclax for 48 h. As positive
controls, to block or induce autophagic flux, cells were incubated with 50 µM chloroquine or 800 nM
rapamycin for 18 h, respectively. The cells were then stained with Cyto-IDTM Green dye and Hoechst
33342 using the Cyto-IDTM Autophagy Detection Kit (Enzo) according to the manufacturer’s protocol,
visualized using an inverted fluorescence microscope (Zeiss, Oberkochen, Germany) and counted
using CellQuest Pro software in a FACScan flow cytometer (BD Biosciences).
4.8. Statistical Analysis
Data comparing differences between two conditions were statistically analyzed, when indicated,
using the paired Student’s t-test. The association between the expression of Mcl-1 and patients’ tumor
infiltration was analyzed using Fisher’s exact test. Recurrence-free survival curve was calculated by
the method of Kaplan and Meier. The comparison of the survival curve was done by the log rank
test of Mantel and Cox. Differences were considered significant when p < 0.05. Calculations were
performed using Prism 6.0 (GraphPad, San Diego, CA, USA).
5. Conclusions
In summary, in this work, we explored the mechanism by which bladder cancer cells can overcome
resistance to paclitaxel by combination treatment with obatoclax. Our results implicate the blockade of
autophagy by the cleavage of beclin-1 as obatoclax-induced mechanisms of sensitization to apoptotic
cell death. Moreover, the inhibition of mitotic slippage observed in paclitaxel-resistant cells (HT1197,
HT1376, and MDA-MB-231) after the combination treatment could represent another mechanism to
overcome paclitaxel resistance. Finally, Mcl-1 expression may be a useful predictive biomarker in
advanced bladder cancer.
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